# Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

> **NCT01098162** · — · COMPLETED · sponsor: **UCB Pharma GmbH** · enrollment: 576 (actual)

## Conditions studied

- Epilepsies, Partial

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01098162
- **Lead sponsor:** UCB Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 576 (ACTUAL)
- **Last updated:** 2014-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01098162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01098162, "Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01098162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*